Biolevate Multi-Dimensional Extraction Test Document

Clinical outcomes summary:

Study ID: NCT-2026-001
Treatment arm: Placebo
Timepoint: Week 12
Outcome value: 18.4
Unit: points on the symptom severity scale
Note: Baseline-adjusted mean change from the randomized population.

Study ID: NCT-2026-001
Treatment arm: Biolevate-101 low dose
Timepoint: Week 12
Outcome value: 24.9
Unit: points on the symptom severity scale
Note: The low dose arm showed a moderate improvement versus placebo.

Study ID: NCT-2026-001
Treatment arm: Biolevate-101 high dose
Timepoint: Week 12
Outcome value: 31.7
Unit: points on the symptom severity scale
Note: The high dose arm met the primary endpoint with p=0.004.

Study ID: NCT-2026-002
Treatment arm: Standard of care
Timepoint: Month 6
Outcome value: 62
Unit: percent response rate
Note: Response was defined as at least a 50 percent reduction in symptoms.

Study ID: NCT-2026-002
Treatment arm: Biolevate-202
Timepoint: Month 6
Outcome value: 78
Unit: percent response rate
Note: The investigational arm had a higher response rate than standard of care.
